Chugai Received the MHLW’s Approval for FoundationOne CDx Cancer Genomic Profile as a Companion Diagnostic for the Detection of Solid Tumor
Shots:
- The company received the MHLW’s approval for FoundationOne CDx Cancer Genomic Profile as a companion diagnostic for Eli Lilly’s Retevmo capsules for the treatment of RET fusion-positive solid tumors
- The companion diagnostic will allow the detection of RET fusion genes by assisting the decision to use selpercatinib for the detection of solid tumors among patients
- Earlier, Eli Lilly evaluated the safety & efficacy of selpercatinib in a P-I/II (LIBRETTO-001) clinical trial among RET fusion-positive solid tumor patients. Additionally, Eli Lilly is currently applying to the MHLW for other indications
Ref: Chugai | Image: Chugai
Related News:- Chugai Reports the NDA Submission of Crovalimab to the MHLW for the Treatment of Paroxysmal Nocturnal Hemoglobinuria in Japan
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
